Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
The New England Journal of Medicine|September 15, 2006
Sirolimus-eluting versus uncoated stents in acute myocardial infarctionChristian Spaulding, Patrick Henry, Emmanuel Teiger, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|January 12, 2019
Cause of death analysis and temporal trends in survival after liver transplantation for transthyretin familial amyloid polyneuropathyVincent Algalarrondo, Teresa Antonini, Marie Théaudin, et al.
JAMA Cardiology|March 17, 2019
Association of Patisiran, an RNA Interference Therapeutic, With Regional Left Ventricular Myocardial Strain in Hereditary Transthyretin Amyloidosis: The APOLLO StudyMasatoshi Minamisawa, Brian Claggett, David Adams, et al.
Archives of Cardiovascular Diseases|January 23, 2026
Associated diseases and diuretic dosage to predict mortality in transthyretin amyloid cardiomyopathyVincent Algalarrondo, Olivier Lairez, Marion Narbeburu, et al.
Circulation|December 28, 2018
Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated AmyloidosisScott D Solomon, David Adams, Arnt Kristen, et al.
European Heart Journal|May 22, 2025
Beta-blocker interruption effects on blood pressure and heart rate after myocardial infarction: the AβYSS trialNiki Procopi, Michel Zeitouni, Mathieu Kerneis, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|August 21, 2016
The Multi-center Evaluation of the Accuracy of the Contrast MEdium INduced Pd/Pa RaTiO in Predicting FFR (MEMENTO-FFR) StudyAntonio Maria Leone, Roberto Martin-Reyes, Sergio B Baptista, et al.
The Lancet. Neurology|November 19, 2020
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension studyDavid Adams, Michael Polydefkis, Alejandra González-Duarte, et al.
Circulation|June 10, 2026
Heart Rate and Cardiovascular Outcomes in Post-Myocardial Infarction Patients Treated by β-Blockers: A Secondary Analysis of the ABYSS TrialMichel Zeitouni, Niki Procopi, Guillaume Cayla, et al.
Revue Neurologique|April 20, 2024
Transthyretin amyloid polyneuropathy in France: A cross-sectional study with 413 patients and real-world tafamidis meglumine use (2009-2019)D Adams, P Cintas, G Solé, et al.
Pageof 7